Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Total Enrollment
1 participants
Study Classification
OBSERVATIONAL
Study Start Date
2019-12-01
Study Completion Date
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
For some neurological and neurodegenerative diseases genetic inheritance is well documented (described as Mendelian or multifactorial), but sometimes specific mutations or family segregation evidences have not been identified. Considering this scenario, most of the times it is impossible or unlikely to identify the responsible gene, or the private mutation, of a patient affected by a neurodegenerative disease.
New technologies such as Next Generation Sequencing (NGS), allow the analysis of hundreds of genes in a single experiment. The implementation of these technologies will help to identify new genes and new variants associated with neurological diseases. Using this approach, several molecular genetic diagnosis will definitely find the needle in a haystack, and will be able to be used in the clinical practice.
New technologies such as Next Generation Sequencing (NGS), allow the analysis of hundreds of genes in a single experiment. The implementation of these technologies will help to identify new genes and new variants associated with neurological diseases. Using this approach, several molecular genetic diagnosis will definitely find the needle in a haystack, and will be able to be used in the clinical practice.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Assessing the Polygenic Burden of Rare Disruptive Mutations in Parkinson's Disease
NCT04620980
Parkinson Disease
UNKNOWN
Finding Genes With NGS Techniques in Whom Mutations Cause Neurological Diseases
NCT02340871
Neurological Diseases
UNKNOWN
Functional Genomics of Rare Genetic Diseases: Realization of Innovative Tools With High Diagnostic Power
NCT04152876
Rare Diseases
UNKNOWN
Genetic Architecture of Chronic Inflammatory Demyelinating Polyradiculoneuropathy
NCT06325878
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
RECRUITING
NA
Genetics of Familial and Sporadic ALS
NCT00821132
Amyotrophic Lateral Sclerosis (ALS)
Familial Amyotrophic Lateral Sclerosis
ALS With Frontotemporal Dementia (ALS/FTD)
+4 more
COMPLETED
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1\. INTRODUCTION
For some neurological and neurodegenerative diseases genetic inheritance is well documented, and guidelins have been improved to ensure a quality diagnostic approach. Unfortunately, this scenario is not reproducible for most of the neurological and neurodegenerative disorders, also when a strong genetic component is documented. This is due to:
* Polygenicity, where different genes can contribute to the same phenotype (eg Spastic Paraplegia, associated with over 50 genes)
* Multifactorial diseases, genetic can explains only a part of the etiology of the disease (such as Parkinson's disease in which the identified genes are responsible for only 15% of patients with a clinical diagnosis)
* Disorders with well established genetic component, but the responsible genes has not been identified.
Therefore, sometimes it impossible or unlikely to complete a molecular diagnosis for patients with a classical or complex phenotypes New technologies such as Next Generation Sequencing (NGS), allow the analysis of hundreds of genes in a single experiment. The implementation of these technologies will help to identify new genes and new variants associate
2\. DESIGN STUDY
The goal of this study is to improve the diagnostic approach in molecular genetics through NGS. This will allow to characterize genomic variations and new genes responsible for neurological and neurodegenerative diseases. In particular, NGS will identify:
1\. New genes associated with diseases characterized by genetic heterogeneity, Mendelian and polygenic heredity.
2\. New variations responsible for disease or that can increase genetic susceptibility.
3\. EXPERIMENTAL PHASE (Attachment 1)
1. Neurology and, if required, Genetic Counseling.
2. Genetic Counseling identifies the molecular analysis for a specific patient. A blood sample of 6 milliliters will be collected after informed consent (informed consent Neuromed version 2.12.2015).
3. Specific guidelines for each test will be followed for the first diagnostic approach. Molecular analyses are carried out at the Institute of Molecular Genetics Center IRCCS INM Neuromed using Sanger sequencing, multiplex ligation-dependent probe amplification (MLPA) and microsatellites.
4. If the specific analysis will not detect the mutations, NGS panel consisting in 4,813 genes associated with known clinical phenotypes (clinical exome, or Mendeliome) will be applied.
4\. MATERIALS AND METHODS
* DNA/RNA EXTRACTION Genomic DNA will be isolated from peripheral blood leukocytes according to standard procedures. Total RNA will be isolated from cultured cells using TRIzol Reagent (Invitrogen, Life Technologies) according to the manufacturer's instructions. The concentration and purity of DNA/RNA samples will be determinate using Nanodrop 2000 (Thermo Scientific, Life Technologies).
* MLPA (Multiplex ligation-dependent probe amplification) MLPA (Multiplex Ligation-dependent Probe Amplification) is a multiplex PCR method detecting abnormal copy numbers of up to 50 different genomic DNA or RNA sequences, which is able to distinguish sequences differing in only one nucleotide.
Typical for MLPA is that it is not target sequences that are amplified, but MLPA probes that hybridise to the target sequence. In contrast to a standard multiplex PCR, a single pair PCR primers is used for MLPA amplification. The resulting amplification products of a SALSA MLPA kits range between 130 and 480 nt in length and can be analysed by capillary electrophoresis. Comparing the peak pattern obtained to that of reference samples indicates which sequences show aberrant copy numbers.
The MLPA reaction can be divided in five major steps: 1) DNA denaturation and hybridisation of MLPA probes; 2) ligation reaction; 3) PCR reaction; 4) separation of amplification products by electrophoresis; and 5) data analysis
• SEQUENCING
The DNA sample to be sequenced is combined in a tube with primer, DNA polymerase, and DNA nucleotides (dATP, dTTP, dGTP, and dCTP). The four dye-labeled, chain-terminating dideoxy nucleotides are added as well, but in much smaller amounts than the ordinary nucleotides.
The mixture is first heated to denature the template DNA (separate the strands), then cooled so that the primer can bind to the single-stranded template. Once the primer has bound, the temperature is raised again, allowing DNA polymerase to synthesize new DNA starting from the primer. DNA polymerase will continue adding nucleotides to the chain until it happens to add a dideoxy nucleotide instead of a normal one. At that point, no further nucleotides can be added, so the strand will end with the dideoxy nucleotide.
This process is repeated in a number of cycles. By the time the cycling is complete, it's virtually guaranteed that a dideoxy nucleotide will have been incorporated at every single position of the target DNA in at least one reaction. That is, the tube will contain fragments of different lengths, ending at each of the nucleotide positions in the original DNA (see figure below). The ends of the fragments will be labeled with dyes that indicate their final nucleotide. After the reaction is done, the fragments are run through a long, thin tube containing a gel matrix in a process called capillary gel electrophoresis. Short fragments move quickly through the pores of the gel, while long fragments move more slowly. As each fragment crosses the "finish line" at the end of the tube, it's illuminated by a laser, allowing the attached dye to be detected.
The smallest fragment (ending just one nucleotide after the primer) crosses the finish line first, followed by the next-smallest fragment (ending two nucleotides after the primer), and so forth. Thus, from the colors of dyes registered one after another on the detector, the sequence of the original piece of DNA can be built up one nucleotide at a time. The data recorded by the detector consist of a series of peaks in fluorescence intensity, as shown in the chromatogram above. The DNA sequence is read from the peaks in the chromatogram.
• MICROSATELLITE Microsatellite analysis includes PCR amplification of the microsatellite loci using fluorescently labeled primers (6-FAM, TET, HEX, NED); labeled PCR products are then analyzed by capillary electrophoresis (ABI PRISM 310 and 3130 XL Applied Biosystem) (CE) or electrophoresis to separate the alleles by size.
The results were processed using the GENESCAN and GENOTYPER5 programs. Once established the values of individual alleles, they were assigned to each individual.
• NEXT GENERATION SEQUENCING (NGS)
In principle, the concept behind NGS technology is similar to CE sequencing-DNA polymerase catalyzes the incorporation of fluorescently labeled deoxyribonucleotide triphosphates (dNTPs) into a DNA template strand during sequential cycles of DNA synthesis. During each cycle, at the point of incorporation, the nucleotides are identified by fluorophore excitation. The critical difference is that, instead of sequencing a single DNA fragment, NGS extends this process across millions of fragments in a massively parallel fashion. Illumina sequencing by synthesis (SBS) chemistry is the most widely adopted chemistry in the industry and delivers the highest accuracy, the highest yield of error-free reads, and the highest percentage of base calls above Q30.6-8 The Illumina NGS workflows include 4 basic steps (Figure 3):
o Library Preparation-The sequencing library is prepared by random fragmentation of the DNA or cDNA sample, followed by 5' and 3' adapter ligation. Alternatively, "tagmentation" combines the fragmentation and ligation reactions into a single step that greatly increases the efficiency of the library preparation process.9 Adapter-ligated fragments are then PCR amplified and gel purified.
o Cluster Generation-For cluster generation, the library is loaded into a flow cell where fragments are captured on a lawn of surface-bound oligos complementary to the library adapters. Each fragment is then amplified into distinct, clonal clusters through bridge amplification. When cluster generation is complete, the templates are ready for sequencing.
o Sequencing-Illumina technology utilizes a proprietary reversible terminator-based method that detects single bases as they are incorporated into DNA template strands. As all 4 reversible terminator-bound dNTPs are present during each sequencing cycle, natural competition minimizes incorporation bias and greatly reduces raw error rates compared to other technologies.6, 7 The result is highly accurate base-by-base sequencing that virtually eliminates sequence-context-specific errors, even within repetitive sequence regions and homopolymers.
o Data Analysis-During data analysis and alignment, the newly identified sequence reads are then aligned to a reference genome. Following alignment, many variations of analysis are possible such as single nucleotide polymorphism (SNP) or insertion-deletion (indel) identification, read counting for RNA methods, phylogenetic or metagenomic analysis, and more.
5\. STATISTICS
In order to determine the pathogenicity of the variants, we will be performed:
* Molecular test in proband's family.
* In-silico analysis by bioinformatics software (Sift: http://sift.jcvi.org/; PolyPhen: http://genetics.bwh.harvard.edu/pph2/).
* Frequency analysis in the general population with SNPs Banks (dbSNP: https: //www.ncbi.nlm.nih.gov/projects/SNP/; EXAC: http://exac.broadinstitute.org/)
6\. ETHICAL ASPECTS This study follow the ethical standards of Helsinki Declaration and its revisions. The study will be conducted taking into account the regulatory requirements and compliance with the law. The informed consent already approved previously by the ethics committee.
For some neurological and neurodegenerative diseases genetic inheritance is well documented, and guidelins have been improved to ensure a quality diagnostic approach. Unfortunately, this scenario is not reproducible for most of the neurological and neurodegenerative disorders, also when a strong genetic component is documented. This is due to:
* Polygenicity, where different genes can contribute to the same phenotype (eg Spastic Paraplegia, associated with over 50 genes)
* Multifactorial diseases, genetic can explains only a part of the etiology of the disease (such as Parkinson's disease in which the identified genes are responsible for only 15% of patients with a clinical diagnosis)
* Disorders with well established genetic component, but the responsible genes has not been identified.
Therefore, sometimes it impossible or unlikely to complete a molecular diagnosis for patients with a classical or complex phenotypes New technologies such as Next Generation Sequencing (NGS), allow the analysis of hundreds of genes in a single experiment. The implementation of these technologies will help to identify new genes and new variants associate
2\. DESIGN STUDY
The goal of this study is to improve the diagnostic approach in molecular genetics through NGS. This will allow to characterize genomic variations and new genes responsible for neurological and neurodegenerative diseases. In particular, NGS will identify:
1\. New genes associated with diseases characterized by genetic heterogeneity, Mendelian and polygenic heredity.
2\. New variations responsible for disease or that can increase genetic susceptibility.
3\. EXPERIMENTAL PHASE (Attachment 1)
1. Neurology and, if required, Genetic Counseling.
2. Genetic Counseling identifies the molecular analysis for a specific patient. A blood sample of 6 milliliters will be collected after informed consent (informed consent Neuromed version 2.12.2015).
3. Specific guidelines for each test will be followed for the first diagnostic approach. Molecular analyses are carried out at the Institute of Molecular Genetics Center IRCCS INM Neuromed using Sanger sequencing, multiplex ligation-dependent probe amplification (MLPA) and microsatellites.
4. If the specific analysis will not detect the mutations, NGS panel consisting in 4,813 genes associated with known clinical phenotypes (clinical exome, or Mendeliome) will be applied.
4\. MATERIALS AND METHODS
* DNA/RNA EXTRACTION Genomic DNA will be isolated from peripheral blood leukocytes according to standard procedures. Total RNA will be isolated from cultured cells using TRIzol Reagent (Invitrogen, Life Technologies) according to the manufacturer's instructions. The concentration and purity of DNA/RNA samples will be determinate using Nanodrop 2000 (Thermo Scientific, Life Technologies).
* MLPA (Multiplex ligation-dependent probe amplification) MLPA (Multiplex Ligation-dependent Probe Amplification) is a multiplex PCR method detecting abnormal copy numbers of up to 50 different genomic DNA or RNA sequences, which is able to distinguish sequences differing in only one nucleotide.
Typical for MLPA is that it is not target sequences that are amplified, but MLPA probes that hybridise to the target sequence. In contrast to a standard multiplex PCR, a single pair PCR primers is used for MLPA amplification. The resulting amplification products of a SALSA MLPA kits range between 130 and 480 nt in length and can be analysed by capillary electrophoresis. Comparing the peak pattern obtained to that of reference samples indicates which sequences show aberrant copy numbers.
The MLPA reaction can be divided in five major steps: 1) DNA denaturation and hybridisation of MLPA probes; 2) ligation reaction; 3) PCR reaction; 4) separation of amplification products by electrophoresis; and 5) data analysis
• SEQUENCING
The DNA sample to be sequenced is combined in a tube with primer, DNA polymerase, and DNA nucleotides (dATP, dTTP, dGTP, and dCTP). The four dye-labeled, chain-terminating dideoxy nucleotides are added as well, but in much smaller amounts than the ordinary nucleotides.
The mixture is first heated to denature the template DNA (separate the strands), then cooled so that the primer can bind to the single-stranded template. Once the primer has bound, the temperature is raised again, allowing DNA polymerase to synthesize new DNA starting from the primer. DNA polymerase will continue adding nucleotides to the chain until it happens to add a dideoxy nucleotide instead of a normal one. At that point, no further nucleotides can be added, so the strand will end with the dideoxy nucleotide.
This process is repeated in a number of cycles. By the time the cycling is complete, it's virtually guaranteed that a dideoxy nucleotide will have been incorporated at every single position of the target DNA in at least one reaction. That is, the tube will contain fragments of different lengths, ending at each of the nucleotide positions in the original DNA (see figure below). The ends of the fragments will be labeled with dyes that indicate their final nucleotide. After the reaction is done, the fragments are run through a long, thin tube containing a gel matrix in a process called capillary gel electrophoresis. Short fragments move quickly through the pores of the gel, while long fragments move more slowly. As each fragment crosses the "finish line" at the end of the tube, it's illuminated by a laser, allowing the attached dye to be detected.
The smallest fragment (ending just one nucleotide after the primer) crosses the finish line first, followed by the next-smallest fragment (ending two nucleotides after the primer), and so forth. Thus, from the colors of dyes registered one after another on the detector, the sequence of the original piece of DNA can be built up one nucleotide at a time. The data recorded by the detector consist of a series of peaks in fluorescence intensity, as shown in the chromatogram above. The DNA sequence is read from the peaks in the chromatogram.
• MICROSATELLITE Microsatellite analysis includes PCR amplification of the microsatellite loci using fluorescently labeled primers (6-FAM, TET, HEX, NED); labeled PCR products are then analyzed by capillary electrophoresis (ABI PRISM 310 and 3130 XL Applied Biosystem) (CE) or electrophoresis to separate the alleles by size.
The results were processed using the GENESCAN and GENOTYPER5 programs. Once established the values of individual alleles, they were assigned to each individual.
• NEXT GENERATION SEQUENCING (NGS)
In principle, the concept behind NGS technology is similar to CE sequencing-DNA polymerase catalyzes the incorporation of fluorescently labeled deoxyribonucleotide triphosphates (dNTPs) into a DNA template strand during sequential cycles of DNA synthesis. During each cycle, at the point of incorporation, the nucleotides are identified by fluorophore excitation. The critical difference is that, instead of sequencing a single DNA fragment, NGS extends this process across millions of fragments in a massively parallel fashion. Illumina sequencing by synthesis (SBS) chemistry is the most widely adopted chemistry in the industry and delivers the highest accuracy, the highest yield of error-free reads, and the highest percentage of base calls above Q30.6-8 The Illumina NGS workflows include 4 basic steps (Figure 3):
o Library Preparation-The sequencing library is prepared by random fragmentation of the DNA or cDNA sample, followed by 5' and 3' adapter ligation. Alternatively, "tagmentation" combines the fragmentation and ligation reactions into a single step that greatly increases the efficiency of the library preparation process.9 Adapter-ligated fragments are then PCR amplified and gel purified.
o Cluster Generation-For cluster generation, the library is loaded into a flow cell where fragments are captured on a lawn of surface-bound oligos complementary to the library adapters. Each fragment is then amplified into distinct, clonal clusters through bridge amplification. When cluster generation is complete, the templates are ready for sequencing.
o Sequencing-Illumina technology utilizes a proprietary reversible terminator-based method that detects single bases as they are incorporated into DNA template strands. As all 4 reversible terminator-bound dNTPs are present during each sequencing cycle, natural competition minimizes incorporation bias and greatly reduces raw error rates compared to other technologies.6, 7 The result is highly accurate base-by-base sequencing that virtually eliminates sequence-context-specific errors, even within repetitive sequence regions and homopolymers.
o Data Analysis-During data analysis and alignment, the newly identified sequence reads are then aligned to a reference genome. Following alignment, many variations of analysis are possible such as single nucleotide polymorphism (SNP) or insertion-deletion (indel) identification, read counting for RNA methods, phylogenetic or metagenomic analysis, and more.
5\. STATISTICS
In order to determine the pathogenicity of the variants, we will be performed:
* Molecular test in proband's family.
* In-silico analysis by bioinformatics software (Sift: http://sift.jcvi.org/; PolyPhen: http://genetics.bwh.harvard.edu/pph2/).
* Frequency analysis in the general population with SNPs Banks (dbSNP: https: //www.ncbi.nlm.nih.gov/projects/SNP/; EXAC: http://exac.broadinstitute.org/)
6\. ETHICAL ASPECTS This study follow the ethical standards of Helsinki Declaration and its revisions. The study will be conducted taking into account the regulatory requirements and compliance with the law. The informed consent already approved previously by the ethics committee.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Genetic Disease
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
CASE_ONLY
Study Time Perspective
OTHER
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
neurological and neurodegenerative diseases
NGS on a large scale of Patients with complexes phenotypes
Intervention Type
GENETIC
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Clinical criteria for neurogenetic disease
Exclusion Criteria
* absence of clinical condition
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Neuromed IRCCS
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Stefano Gambardella
Biologist, PhD
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Stefano Gambardella, PhD
Role: PRINCIPAL_INVESTIGATOR
IRCCS Neuromed INM
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Stefano Gambardella
Pozzilli, Isernia, Italy
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Italy
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Zhi D, Chen R. Statistical guidance for experimental design and data analysis of mutation detection in rare monogenic mendelian diseases by exome sequencing. PLoS One. 2012;7(2):e31358. doi: 10.1371/journal.pone.0031358. Epub 2012 Feb 10.
Reference Type
RESULT
Wheeler DA, Srinivasan M, Egholm M, Shen Y, Chen L, McGuire A, He W, Chen YJ, Makhijani V, Roth GT, Gomes X, Tartaro K, Niazi F, Turcotte CL, Irzyk GP, Lupski JR, Chinault C, Song XZ, Liu Y, Yuan Y, Nazareth L, Qin X, Muzny DM, Margulies M, Weinstock GM, Gibbs RA, Rothberg JM. The complete genome of an individual by massively parallel DNA sequencing. Nature. 2008 Apr 17;452(7189):872-6. doi: 10.1038/nature06884.
Reference Type
RESULT
Voelkerding KV, Dames SA, Durtschi JD. Next-generation sequencing: from basic research to diagnostics. Clin Chem. 2009 Apr;55(4):641-58. doi: 10.1373/clinchem.2008.112789. Epub 2009 Feb 26.
Reference Type
RESULT
Tucker T, Marra M, Friedman JM. Massively parallel sequencing: the next big thing in genetic medicine. Am J Hum Genet. 2009 Aug;85(2):142-54. doi: 10.1016/j.ajhg.2009.06.022.
Reference Type
RESULT
Teer JK, Mullikin JC. Exome sequencing: the sweet spot before whole genomes. Hum Mol Genet. 2010 Oct 15;19(R2):R145-51. doi: 10.1093/hmg/ddq333. Epub 2010 Aug 12.
Reference Type
RESULT
Singleton AB. Exome sequencing: a transformative technology. Lancet Neurol. 2011 Oct;10(10):942-6. doi: 10.1016/S1474-4422(11)70196-X.
Reference Type
RESULT
Ng SB, Buckingham KJ, Lee C, Bigham AW, Tabor HK, Dent KM, Huff CD, Shannon PT, Jabs EW, Nickerson DA, Shendure J, Bamshad MJ. Exome sequencing identifies the cause of a mendelian disorder. Nat Genet. 2010 Jan;42(1):30-5. doi: 10.1038/ng.499. Epub 2009 Nov 13.
Reference Type
RESULT
Mamanova L, Coffey AJ, Scott CE, Kozarewa I, Turner EH, Kumar A, Howard E, Shendure J, Turner DJ. Target-enrichment strategies for next-generation sequencing. Nat Methods. 2010 Feb;7(2):111-8. doi: 10.1038/nmeth.1419.
Reference Type
RESULT
Li H, Ruan J, Durbin R. Mapping short DNA sequencing reads and calling variants using mapping quality scores. Genome Res. 2008 Nov;18(11):1851-8. doi: 10.1101/gr.078212.108. Epub 2008 Aug 19.
Reference Type
RESULT
Ferese R, Campopiano R, Scala S, D'Alessio C, Storto M, Buttari F, Centonze D, Logroscino G, Zecca C, Zampatti S, Fornai F, Cianci V, Manfroi E, Giardina E, Magnani M, Suppa A, Novelli G, Gambardella S. Cohort Analysis of 67 Charcot-Marie-Tooth Italian Patients: Identification of New Mutations and Broadening of Phenotype Expression Produced by Rare Variants. Front Genet. 2021 Jul 19;12:682050. doi: 10.3389/fgene.2021.682050. eCollection 2021.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CGM-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Study of Clinical and Molecular Manifestations of Genetic Disorders
NCT00001466
COMPLETED
Investigating Genetic Status in Patients Presenting to Clinic
NCT05911932
RECRUITING
Study of Inherited Neurological Disorders
NCT00004568
RECRUITING
Genetic Profile In Patients With Ruptured and Unruptured Intracranial Aneurysms
NCT07233915
RECRUITING
Genetic Characterization of Movement Disorders and Dementias
NCT02014246
RECRUITING
Clinical and Genetic Evaluation of Individuals With Undiagnosed Disorders Through the Undiagnosed Diseases Network
NCT02450851
RECRUITING
Establishment of Genetic Basis for Neurological Disease by Genetic Screening
NCT03322306
ENROLLING_BY_INVITATION
Cause and Pathogenesis of Neurometabolic Disorders
NCT00016562
COMPLETED
Genetics of Motor Learning
NCT01105845
TERMINATED
Genotype/Phenotype Correlation of Movement Disorders and Other Neurological Diseases
NCT00001667
COMPLETED
Use of Omics Methods to Classify Variations of Uncertain Significance and Improve Diagnosis of Neurogenetic Diseases
NCT06955624
RECRUITING
NA
Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations
NCT00136630
COMPLETED
Phenotype/Genotype Correlations in Neuromuscular Disorders
NCT00017745
COMPLETED
Protective Genetic Factors Against Neurological Diseases
NCT03914599
COMPLETED
Identification of New FTLD Genes
NCT02363062
UNKNOWN
Biomarkers in Neurodegenerative Diseases
NCT04055532
WITHDRAWN
Molecular Genetics of Schizophrenia
NCT00006418
COMPLETED
Investigating the Feasibility and Implementation of Whole Genome Sequencing in Patients With Suspected Genetic Disorder
NCT03829176
COMPLETED
NA
Initiative for Clinical Long-read Sequencing
NCT06060184
NOT_YET_RECRUITING
NA
Next Generation Sequencing Analysis of Patients with Spontaneous Dissection of Cervical Arteries
NCT06862063
RECRUITING
NA
Genetics of Cardiovascular and Neuromuscular Disease
NCT00138931
RECRUITING
Various Type of Genetic Events in Patients With Intellectual Disability
NCT02881333
UNKNOWN
Genetics of Mendelian Forms of Young Onset Alzheimer Disease
NCT01622894
COMPLETED
Phenotype/Genotype Correlations in Movement Disorders
NCT00018889
RECRUITING